Handelsbanken Fonder AB Buys 72,596 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Handelsbanken Fonder AB grew its position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 38.7% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 260,000 shares of the company's stock after purchasing an additional 72,596 shares during the period. Handelsbanken Fonder AB owned about 0.24% of NewAmsterdam Pharma worth $5,322,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Avanza Fonder AB bought a new stake in shares of NewAmsterdam Pharma in the 1st quarter valued at about $127,000. Wellington Management Group LLP increased its holdings in shares of NewAmsterdam Pharma by 2,410.4% during the 4th quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock worth $59,499,000 after acquiring an additional 2,222,900 shares during the last quarter. California State Teachers Retirement System grew its position in shares of NewAmsterdam Pharma by 23.5% in the fourth quarter. California State Teachers Retirement System now owns 19,404 shares of the company's stock valued at $499,000 after purchasing an additional 3,694 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of NewAmsterdam Pharma during the 4th quarter worth approximately $50,000. Finally, Frazier Life Sciences Management L.P. raised its stake in NewAmsterdam Pharma by 23.8% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company's stock valued at $409,052,000 after purchasing an additional 3,061,224 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company's stock.

Analysts Set New Price Targets

NAMS has been the topic of a number of research analyst reports. Cantor Fitzgerald started coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 target price on the stock. Scotiabank lifted their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Thursday, February 27th. Needham & Company LLC reissued a "buy" rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday. Stifel Nicolaus initiated coverage on NewAmsterdam Pharma in a report on Tuesday. They issued a "buy" rating and a $44.00 target price for the company. Finally, UBS Group set a $41.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $43.00.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director James N. Topper purchased 1,135 shares of the firm's stock in a transaction that occurred on Wednesday, March 26th. The stock was bought at an average cost of $22.49 per share, with a total value of $25,526.15. Following the completion of the transaction, the director now owns 3,013,569 shares of the company's stock, valued at $67,775,166.81. The trade was a 0.04% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 20.84% of the company's stock.

NewAmsterdam Pharma Stock Performance

NAMS traded down $0.82 during mid-day trading on Friday, reaching $20.21. 550,120 shares of the stock were exchanged, compared to its average volume of 679,365. NewAmsterdam Pharma has a 1 year low of $14.06 and a 1 year high of $27.29. The stock has a market capitalization of $2.27 billion, a PE ratio of -10.75 and a beta of -0.03. The company has a 50 day moving average price of $18.09 and a two-hundred day moving average price of $20.86.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The company had revenue of $2.98 million for the quarter, compared to analyst estimates of $1.46 million. Sell-side analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.